MEG3 Activated by Vitamin D Inhibits Colorectal Cancer Cells Proliferation and Migration Via Regulating Clusterin

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2018 Apr 10

PMID 29628342

Citations 42

Authors

Yan Zhu

Peizhan Chen

Yisha Gao

Na Ta

Yunshuo Zhang

Jialin Cai

Yong Zhao

Shupeng Liu

Jianming Zheng

Affiliations

Soon will be listed here.

Abstract

The long non-coding RNA maternally expressed gene 3 (MEG3) is frequently dysregulated in human cancers; however, its roles in colorectal cancer (CRC) development are largely unknown. Here, we reported that MEG3 was down-regulated in CRC tissues and CRC patients with lower MEG3 showed poorer overall survival and disease-free survival than those with higher MEG3 level. MEG3 over-expression represses CRC cells proliferation and migration in vivo and in vitro, while MEG3 knockdown leads to the enhanced proliferation and metastasis of CRC cells. In CRC cells, MEG3 over-expression is related to decreased Clusterin mRNA and the corresponding protein levels, and it also directly binds to Clusterin protein through its 732-1174 region. In further, Clusterin over-expression rescues the compromised abilities of proliferation and metastasis induced by MEG3 over-expression, suggesting that MEG3 inhibits the CRC progression through regulating the Clusterin activities. Additionally, we found that 1α,25-(OH)D and vitamin D receptor (VDR) stimulate MEG3 expression in CRC cells through directly binding to its promoter. These results suggested that MEG3 functions as a tumor suppressor in CRC via regulating the Clusterin activities and may underlie the anticancer activities of vitamin D on CRC cells. The VDR/MEG3/Clusterin signaling pathway may serve as potential therapeutic targets and prognosis biomarkers for CRC patients in future.

Citing Articles

Identification of MYC and STAT3 for early diagnosis based on the long noncoding RNA-mRNA network and bioinformatics in colorectal cancer.

Yao K, Fan H, Yang T, Yang C, Wang G, Li X Front Immunol. 2025; 15():1497919.

PMID: 39830506 PMC: 11739134. DOI: 10.3389/fimmu.2024.1497919.

Harnessing the TP53INP1/TP53I3 axis for inhibition of colorectal cancer cell proliferation through MEG3 and Linc-ROR Co-expression.

Ramezani M, Shamsabadi F, Shahbazi M Heliyon. 2024; 10(14):e34075.

PMID: 39108882 PMC: 11301216. DOI: 10.1016/j.heliyon.2024.e34075.

Therapeutic Potential of Clusterin Inhibition in Human Cancer.

Martin-Garcia D, Garcia-Aranda M, Redondo M Cells. 2024; 13(8.

PMID: 38667280 PMC: 11049052. DOI: 10.3390/cells13080665.

Tracing vitamins on the long non-coding lane of the transcriptome: vitamin regulation of LncRNAs.

Yazarlou F, Alizadeh F, Lipovich L, Giordo R, Ghafouri-Fard S Genes Nutr. 2024; 19(1):5.

PMID: 38475720 PMC: 10935982. DOI: 10.1186/s12263-024-00739-4.

Clusterin: a marker and mediator of chemoresistance in colorectal cancer.

Hlavca S, Chan W, Engel R, Abud H Cancer Metastasis Rev. 2024; 43(1):379-391.

PMID: 38319453 PMC: 11015998. DOI: 10.1007/s10555-024-10173-y.

References

Elimrani I, Koenekoop J, Dionne S, Marcil V, Delvin E, Levy E . Vitamin D Reduces Colitis- and Inflammation-Associated Colorectal Cancer in Mice Independent of NOD2. Nutr Cancer. 2017; 69(2):276-288. DOI: 10.1080/01635581.2017.1263346. View

Jiang Y, Bikle D . LncRNA: a new player in 1α, 25(OH)(2) vitamin D(3) /VDR protection against skin cancer formation. Exp Dermatol. 2014; 23(3):147-50. PMC: 4103949. DOI: 10.1111/exd.12341. View

Menigatti M, Staiano T, Manser C, Bauerfeind P, Komljenovic A, Robinson M . Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions. Oncogenesis. 2013; 2:e56. PMC: 3740287. DOI: 10.1038/oncsis.2013.21. View

Li Y, Lu J, Zhou S, Wang W, Tan G, Zhang Z . Clusterin induced by N,N'-Dinitrosopiperazine is involved in nasopharyngeal carcinoma metastasis. Oncotarget. 2015; 7(5):5548-63. PMC: 4868705. DOI: 10.18632/oncotarget.6750. View

Lee J, Kim H, Rho S, Lee S . eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells. Oncotarget. 2016; 7(14):18541-57. PMC: 4951308. DOI: 10.18632/oncotarget.8105. View

Walsh J, Terdiman J . Colorectal cancer screening: scientific review. JAMA. 2003; 289(10):1288-96. DOI: 10.1001/jama.289.10.1288. View

Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M . Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties. EBioMedicine. 2017; 19:18-30. PMC: 5440601. DOI: 10.1016/j.ebiom.2017.04.014. View

Bando T, Kato Y, Ihara Y, Yamagishi F, Tsukada K, Isobe M . Loss of heterozygosity of 14q32 in colorectal carcinoma. Cancer Genet Cytogenet. 1999; 111(2):161-5. DOI: 10.1016/s0165-4608(98)00242-8. View

Ponting C, Oliver P, Reik W . Evolution and functions of long noncoding RNAs. Cell. 2009; 136(4):629-41. DOI: 10.1016/j.cell.2009.02.006. View

10.

Marchese F, Raimondi I, Huarte M . The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 2017; 18(1):206. PMC: 5663108. DOI: 10.1186/s13059-017-1348-2. View

11.

Yan H, Xue G, Mei Q, Wang Y, Ding F, Liu M . Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J. 2009; 28(18):2719-32. PMC: 2750010. DOI: 10.1038/emboj.2009.214. View

12.

Pan Y, Cao F, Guo A, Chang W, Chen X, Ma W . Endoplasmic reticulum ribosome-binding protein 1, RRBP1, promotes progression of colorectal cancer and predicts an unfavourable prognosis. Br J Cancer. 2015; 113(5):763-72. PMC: 4559827. DOI: 10.1038/bjc.2015.260. View

13.

Morales-Oyarvide V, Meyerhardt J, Ng K . Vitamin D and Physical Activity in Patients With Colorectal Cancer: Epidemiological Evidence and Therapeutic Implications. Cancer J. 2016; 22(3):223-31. PMC: 4922494. DOI: 10.1097/PPO.0000000000000197. View

14.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

15.

Jiang Y, Bikle D . LncRNA profiling reveals new mechanism for VDR protection against skin cancer formation. J Steroid Biochem Mol Biol. 2013; 144 Pt A:87-90. DOI: 10.1016/j.jsbmb.2013.11.018. View

16.

Deng J, He M, Chen L, Chen C, Zheng J, Cai Z . The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival. PLoS One. 2013; 8(10):e76450. PMC: 3792981. DOI: 10.1371/journal.pone.0076450. View

17.

Lin J, Qiu M, Xu R, Dobs A . Comparison of survival and clinicopathologic features in colorectal cancer among African American, Caucasian, and Chinese patients treated in the United States: Results from the surveillance epidemiology and end results (SEER) database. Oncotarget. 2015; 6(32):33935-43. PMC: 4741814. DOI: 10.18632/oncotarget.5223. View

18.

Duffy M, Murray A, Synnott N, ODonovan N, Crown J . Vitamin D analogues: Potential use in cancer treatment. Crit Rev Oncol Hematol. 2017; 112:190-197. DOI: 10.1016/j.critrevonc.2017.02.015. View

19.

Su L, Han D, Wu J, Huo X . Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163. Tumour Biol. 2015; 37(3):3925-31. DOI: 10.1007/s13277-015-4151-2. View

20.

Wang C, Jin G, Jin H, Wang N, Luo Q, Zhang Y . Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma. Oncotarget. 2015; 6(5):2903-16. PMC: 4413626. DOI: 10.18632/oncotarget.3093. View